1.	Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma Who Have Been Treated With One Prior Therapy Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ARQ197-A-U303, NCT01755767
2.	An Extension Protocol for Subjects Who Were Previously Enrolled in Other ARQ 197 Protocols Phase: Phase II, Phase I Type: Treatment Status: Active Age: Not specified Sponsor: Pharmaceutical / Industry Protocol IDs: ARQ 197-299, NCT01178411
3.	Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 anad over Sponsor: Other Protocol IDs: SCRI GI 157, NCT01611857
4.	Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ARQ 197-218, NCT01395758
5.	c-Met Inhibitor ARQ 197 (Tivantinib) in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2011-03470, 2011-0197, U01CA062461, N01CM00039, MDA-2011-0197, 8984, NCT01447914
6.	Tivantinib in Treating Patients With Metastatic Prostate Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2012-00237, OSU 11132, CDR0000721410, N01CM00070, U01CA062491, N01CM00071, 8986, NCT01519414
7.	ARQ197 in Metastatic Triple-Negative Breast Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18and over Sponsor: Other Protocol IDs: 12-017, NCT01542996
8.	Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2012-00722, 12-017, U01CA062490, CDR0000730102, DFCI-12-017, 8985, NCT01575522
9.	Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot be Removed by Surgery Phase: Phase II Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment Status: Active Age: Not specified Sponsor: NCI Protocol IDs: NCI-2012-01641, S1107, U10CA032102, NCT01688973
10.	Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed By Surgery Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2012-01640, 12-1359, N01CM00071, NCT01696955
11.	Pazopanib and ARQ 197 for Advanced Solid Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 120009, 12-C-0009, NCT01468922
12.	Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects Phase: Phase I Type: Biomarker/Laboratory analysis Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ARQ197-A-U158, NCT01517399
13.	Tivantinib and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2012-00949, CO 11914, U01CA062491, NCT01625156
14.	Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors or Recurrent Small Cell Lung Cancer Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2012-01220, PHI-68, U01CA062505, NCT01654965
15.	Study of ARQ 197 in Hepatocellular Carcinoma (HCC) Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 20 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ARQ 197-008, NCT01656265
16.	Effect of Tivantinib on the QTC Interval in Cancer Subjects Phase: Phase I Type: Biomarker/Laboratory analysis, Supportive care Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ARQ197-A-U-159, NCT01699061
17.	Tivantinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 13 months to 21 years Sponsor: NCI Protocol IDs: NCI-2012-02163, ADVL1111, U01CA097452, NCT01725191
18.	Tivantinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2012-02765, UPCI 12-085, U01CA099168, NCT01749384